The univariable log-rank test showed that GBM IDH-WT patients harboring RB1 mutations (n = 28) had an improved OS compared to RB1-WT (n = 254) patients (23.5 vs 17.7 months, P = .026; Supplementary Figure S2C). This evidence concerns the gene IDH1 and glioblastoma.